The difficult quest for data on "vanishing" vaccine-preventable infections in Europe: the case of measles in Flanders (Belgium)

被引:19
作者
Beutels, P
Van Damme, P
Van Casteren,V
Gay, NJ
De Schrijver, K
Meheus, A
机构
[1] Univ Instelling Antwerp, Ctr Evaluat Vaccinat Epidemiol & Community Med, B-2610 Antwerp, Belgium
[2] Sci Inst Publ Hlth, Epidemiol Sect, Brussels, Belgium
[3] Ctr Communicable Dis Surveillance, Div Immunizat, Publ Hlth Lab, London, England
[4] Minist Flemish Community, Hlth Inspect, Antwerp, Belgium
关键词
measles; vaccination; cost;
D O I
10.1016/S0264-410X(02)00335-3
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We aimed to describe the impact of vaccination on the epidemiology of measles infection in Flanders (Belgium), to document probable vaccination coverage based on this evidence, compare these epidemiological data with those generated by a mathematical model and estimate the costs of morbidity from measles. In contrast to previous analyses, we included the costs of long-term care for sequelae due to encephalitis and subacute sclerosing panencephalitis (SSPE). We estimated the direct health care costs per average measles case at EURO 227, 212, 210, 200 and 194 for the age groups of 0-4, 5-9, 10-14, 15-19 and greater than or equal to20 years, respectively. Excluding long-term care lowers these estimates by 22-51%, depending on the age group. By including indirect time costs, we arrive at total costs per measles case of euro 320, 305, 210, 200 and 625, respectively. In addition to registering vaccination coverage more rigorously in the future, it seems necessary to undertake seroprevalence studies to document the age-specific immunity to measles. By using such information, current vaccination strategies can be adapted to prevent future outbreaks and to help eliminate measles from Europe in an efficient way. We noted throughout that many of the data sources are flawed. Better and accessible data bases are required to improve the reliability of similar studies in the future. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:3551 / 3559
页数:9
相关论文
共 27 条
  • [1] ANDERSON R, 1996, OXFORD TXB PUBLIC HL, P689
  • [2] ANDERSON R M, 1991
  • [3] [Anonymous], 2001, WORLD HLTH REP
  • [4] PREDICTING THE IMPACT OF MEASLES VACCINATION IN ENGLAND AND WALES - MODEL VALIDATION AND ANALYSIS OF POLICY OPTIONS
    BABAD, HR
    NOKES, DJ
    GAY, NJ
    MILLER, E
    MORGANCAPNER, P
    ANDERSON, RM
    [J]. EPIDEMIOLOGY AND INFECTION, 1995, 114 (02) : 319 - 344
  • [5] BEUTELS P, 2000, 36 ESOC ANTW U
  • [6] BEUTELS P, EC EVALUATION OPTION
  • [7] CDC, 1981, MMWR-MORBID MORTAL W, V31, P217
  • [8] De Schrijver K, 1996, Euro Surveill, V1, P46
  • [9] DELPINAL BT, 1983, AN ESP PEDIATR, V19, P383
  • [10] Measles vaccines - A review of adverse events
    Duclos, P
    Ward, BJ
    [J]. DRUG SAFETY, 1998, 19 (06) : 435 - 454